- Home
- / Insys Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Insys Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2020-03-25
Market Capitalization
$3.1 M
2020-03-25
Revenue
$82.1 M
FY, 2018
CreditSafe Score
?
Score changed on Jun 13, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|---|---|---|
| Revenue | 99.3M | 222.1M | 330.8M | 242.3M | 140.7M | 82.1M |
| Revenue growth, % | 123.7% | 48.9% | -26.8% | |||
| Cost of goods sold | 12.7M | 22.6M | 28.9M | 25.4M | 20.6M | 10.8M |
| Gross profit | 86.6M | 199.5M | 301.9M | 216.9M | 120.1M | 71.3M |
| Gross profit margin, % | 87.2% | 89.8% | 91.3% | 89.5% | 85.3% | 86.8% |
| General and administrative expense | 16.4M | 44.3M | 64.0M | 62.1M | 67.6M | 39.3M |
| Operating expense total | 54.1M | 135.5M | 209.5M | 209.6M | 339.1M | 199.0M |
| EBIT | 32.6M | 64.0M | 92.4M | 7.3M | (219.0M) | (127.7M) |
| EBIT margin, % | 32.8% | 28.8% | 27.9% | 3.0% | -155.7% | -155.6% |
| Interest income | 151.0K | 502.0K | 1.0M | 1.9M | 2.0M | |
| Interest expense | 928.0K | 153.0K | 538.0K | 1.1M | 1.8M | 1.3M |
| Pre tax profit | 31.6M | 64.2M | 93.0M | 8.4M | (217.2M) | (126.4M) |
| Income tax expense | (8.8M) | 26.2M | 34.5M | 834.0K | 10.8M | (1.9M) |
| Net Income | 40.4M | 38.0M | 58.5M | 7.6M | (228.0M) | (124.5M) |